Mirati’s Adagrasib Challenger Fails To Differentiate Itself From Amgen’s Lumakras
While adagrasib showed decent efficacy in its pivotal study in NSCLC, some analysts said its inability to outperform Amgen’s Lumakras and its safety profile leave little room for differentiation.
You may also be interested in...
While the big pharma names dominate the ASCO cancer congress, it is also a chance to shine for emerging small-to-medium biopharma companies.
Emerging Company Profile: The private German biotech Ariceum has just launched with a €25m financing to advance its lead radioligand candidate, satoreotide, into Phase I development and hopes its antagonist approach could give Novartis’s Lutathera a run for its money.
The US firm released promising interim data from a mid-stage Becker muscular dystrophy trial, claiming success here could translate to Duchenne as it unveiled plans for more studies across similar conditions.